Macupatide / Obesity / Overweight · Phase 2 Trial

A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes

ClinicalTrials.gov · September 8, 2026

Preliminary Why this matters to you Expert discussion

Early or partial results. Treat as a signal, not a conclusion.

AI Summary

This is a Phase 2 trial registration for a study of two novel obesity and diabetes agents (macupatide and eloralintide), alone or combined, versus placebo in adults with obesity/overweight and type 2 diabetes. No results are posted in this registry record; the study is currently recruiting and outcomes will not be available until completion.

What was studied

Phase 2, Interventional, Randomized, Parallel, Double masking, Treatment purpose. Obesity, Overweight, Diabetes Mellitus, Type 2; age from 18 Years; to 75 Years. Intervention: Macupatide (Macupatide + Eloralintide Placebo); Eloralintide (Elorlintide + Macupatide Placebo); Macupatide + Eloralintide. Compared with: Placebo (Macupatide Placebo + Elorlintide Placebo) — Placebo Comparator. n = 200. 42 sites across 4 countries.

Key findings

Safety

No efficacy or safety data are available

Who this may help

Results from this trial, when published, may inform the efficacy and safety profile of dual GLP-1 receptor agonist and GCG receptor agonist therapy for weight loss in patients with concurrent diabetes. Current registry record provides no evidence on which to base clinical decisions.

Plain-language summary

This is a Phase 2 trial registration with no reported results; the study is actively recruiting and outcome data are not yet available.

Study design

As stated by the source record.

MethodsPrimary outcome measure: Percent Change from Baseline in Body Weight (assessed at Baseline, Week 32)

DesignPhase 2, Interventional, Randomized, Parallel, Double masking, Treatment purpose

PopulationObesity, Overweight, Diabetes Mellitus, Type 2; age from 18 Years; to 75 Years

Sample size200

InterventionMacupatide (Macupatide + Eloralintide Placebo); Eloralintide (Elorlintide + Macupatide Placebo); Macupatide + Eloralintide

ComparatorPlacebo (Macupatide Placebo + Elorlintide Placebo) — Placebo Comparator

Setting42 sites across 4 countries

Reported figures

Quoted from the source exactly as published.

Planned enrollment200

Study phasePhase 2

Primary outcome measurePercent change from baseline in body weight at week 32

Study duration48 weeks

Clinical bottom line

Caveats

No results are reported in this registry record; study is actively recruiting
Blinding status, allocation concealment, and other risk-of-bias details are not described
Primary outcome assessment timing (week 32) and secondary outcomes are not detailed in this extract
No efficacy or safety data are available

Evidence assessment

Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.

Study design

moderate

Phase 2 interventional trial with placebo comparators; design supports early efficacy exploration.

Directness

strong

Primary outcome is percent change in body weight, a clinically relevant endpoint in obesity.

Consistency

insufficient

No results reported; consistency cannot be assessed.

Risk of bias

insufficient

Registry record does not describe blinding, allocation concealment, or other bias mitigation.

Sample adequacy

limited

Estimated 200 participants for Phase 2 exploratory study with multiple arms and comparisons.

What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.

Source abstract

Registry record from ClinicalTrials.gov (NCT07215559). This is a study registration, not published results. Lead sponsor: Eli Lilly and Company. Recruitment status: RECRUITING. Phase: PHASE2. Study type: INTERVENTIONAL. Enrollment: 200 participants (ESTIMATED). Conditions: Obesity, Overweight, Diabetes Mellitus, Type 2. Interventions: DRUG: Macupatide; DRUG: Eloralintide; DRUG: Macupatide Placebo; DRUG: Eloralintide Placebo. Primary outcome measures: Percent Change from Baseline in Body Weight , Baseline, Week 32. Brief summary: The purpose of this study is to investigate weight reduction with macupatide and eloralintide, alone or in combination, in adult participants with obesity or overweight and with type 2 diabetes. Participation in the study will last about 48 weeks.

Follow from this

Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.

MacupatideEli Lilly and CompanyObesityOverweightDiabetes Mellitus, Type 2Eloralintide PlaceboNCT07215559Macupatide PlaceboEloralintide